Vcare PharmaTech Completes Full Participant Enrollment in Phase III Clinical Trial of VC005 Topical Gel, Balanced, Highly Selective New-Generation JAK1 Inhibitor, for Atopic Dermatitis
Published Time:
2026-10-20 17:57
Source:
Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) recently announced that its self-developed VC005 topical gel, balanced, highly selective new-generation JAK1 inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD) in adults and adolescents, has successfully completed full participant enrollment in its Phase III clinical trial. This milestone marks steady progress for the topical product toward the NDA.
As a core asset in Vcare PharmaTech’s autoimmune pipeline, VC005 topical gel is administered topically to act directly on lesional skin. It delivers local therapeutic effects with minimal systemic exposure. While optimizing anti-inflammatory efficacy, the gel relieves pruritus more rapidly and maximizes medication safety. It achieves an improved clinical balance between maximal efficacy and favorable tolerability, catering to the needs of long-term, intermittent topical treatment for patients with mild-to-moderate AD. The enrolled Phase III study is a multicenter, randomized, double-blind, placebo-controlled trial. It will further validate the efficacy and safety of VC005 gel in a larger cohort of adult and adolescent subjects with mild-to-moderate AD, generating core evidence for subsequent new drug registration and filing.
About VC005 Topical Gel
VC005 is a balanced, highly selective next-generation JAK1 inhibitor. It exerts potent inhibition of JAK1 combined with moderate inhibition of TYK2 to target the Th2/Th1/Th17 inflammatory axes for improved overall therapeutic efficacy. Currently, both oral and topical formulations in multiple strengths have been developed, forming a product portfolio covering a wide range of indications. The VC005 topical gel adopts a unique pharmaceutical base, it supports high drug loading while maintaining robust stability, favorable safety profile without irritation, and a light, refreshing gel texture to improve patient adherence.In the completed Phase II clinical trial for mild-to-moderate atopic dermatitis, VC005 topical gel demonstrated notable pruritus relief and lesion improvement at the early stage of treatment. Pruritus relief was observed on Day 1, with an approximate 14% reduction in the mean NRSfor pruritus within 12 hours. Around 30% of subjects achieved ≥50% improvement in eczema area and severity index (EASI-50 response) after one week of dosing, translating to meaningful improvements in patients’ quality of life. In terms of safety, the incidence of TRAEswas lower than that of the vehicle group, with no SARsreported and favorable patient tolerability. Pharmacokinetic data showed extremely low plasma exposure, even lower in adolescent populations, with no drug accumulation. VC005 is expected to address the black box warning concerns associated with marketed topical agents of the same target.
About Atopic Dermatitis
Atopic dermatitis (AD) is a chronic, recurrent, inflammatory skin disease characterized by dry skin, intense pruritus, and eczematous rashes, which severely impacts patients' quality of life. Epidemiologically, the global prevalence of AD is approximately 230 million people. In China, the prevalence of AD among adults ranges from 2% to 8%, with over 70 million patients, including 67% with mild cases and 33% with moderate-to-severe cases. According to F&S forecasts, the number of patients will continue to grow at a CAGRof 1.7% from 2025 to 2030. Traditional therapeutic drugs, such as glucocorticoids, are associated with numerous adverse reactions and fail to provide long-term benefits, making it difficult to achieve effective and stable disease control. In contrast, topical small-molecule JAK1-targeted inhibitors are non-glucocorticoid immunosuppressants, which are expected to retain therapeutic efficacy with further improvement in the medication safety for patients with mild-to-moderate symptoms.
Disclaimer
1.This press release shares cutting‑edge R&D progress of the Company for informational purposes only and is not intended for advertising. Information herein is not directed at patients and is for reference by healthcare professionals only.
2.Nothing in this press release constitutes a recommendation for any medicinal product and/or indication.
3.All information contained herein is for reference only. Company press releases and announcements shall in no way substitute for professional medical advice and shall not be construed as medical guidance. Please consult physicians or other qualified healthcare professionals for disease‑specific diagnosis and treatment advice.
4.As of the release date of this document, VC005 Topical Gel have not obtained marketing approval from the NMPA.
5.This press release may contain certain forward‑looking statements. Such statements inherently carry substantial risks and uncertainties. Words including “anticipate”, “believe”, “forecast”, “expect”, “intend” and other similar expressions in connection with the Company constitute forward‑looking statements. The Company assumes no obligation to update such predictive statements on an ongoing basis.
Forward‑looking statements are based on management’s current views, assumptions, expectations, estimates, forecasts and understanding of future events as of the time of issuance. They are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and difficult to predict. Accordingly, actual outcomes may differ materially from those reflected in forward‑looking statements due to future changes and developments in our business, competitive landscape, political, economic, legal and social conditions.
Neither the Company nor its directors, employees or agents shall bear any liability for (a) any obligation to correct or update forward‑looking statements published on this website; and (b) any liability arising from the non‑realization or inaccuracy of any forward‑looking statements.
Related News
15
2017
/
09
Jiangsu Vcare’s New R&D Center and Headquarter are being constructed
Jiangsu Vcare Pharmaceutical Technology Co., Ltd. bought a 20 mu of land in Biomedical Valley, Nanjing High-tech Industrial Development Zone, Jiangbei New District on August 15, 2017. The area is equipped with metro line 3 and the subway S8. It is about 4 kilometers away from the Nanjing High-speed Railway North Station which is under construction. The surrounding environment is very beautiful and the traffic is very convenient. It is constructed as Vcare’s headquarter and drug research and development center and the center was put into use at the end of 2019.
31
2017
/
08
Jiangsu Vcare Held “Team Building Training” Activity
Jiangsu Vcare held “Team Building Training” activity in the town of Chaxi at the end of August. The activity was divided into several parts and each task is completed within specified time. Participants need to communicate and coordinate with team awareness.
31
2017
/
08
Jiangsu Vcare Held Ten Kilometers Run Activity
87 participants arrived at the main entrance of Xuanwu Lake to participate in a ten-kilometer running activity after warm-up at 7 o'clock on August 31. Six colleagues on a business trip in Hainan and seven colleagues on a business trip in Xi'an also actively participated in the running at the local. Everyone completed the ten-kilometer running after one hour and a half and was very happy to give a test to our physical fitness through the running.
23
2017
/
08
Jiangsu Vcare Was Honored as Jiangbei New Area Lingque Enterprise
In 2017, the list of “Lingque” enterprises in Jiangbei New District of Nanjing was announced and Jiangsu Vcare Pharmaceutical Technology Co., Ltd. was successfully selected into the list. “Lingque” enterprises project aim to select a group of innovative SMEs with high growth in Jiangbei district and provide the selected enterprises with one-stop support such as equity investment, emergency turnover, loan interest subsidy, R&D subsidies, and etc.. To be successfully selected into the “Lingque” enterprises program is an inspiration to the company. Vcare keep integrating various resources to quickly become bigger and stronger to contribute to the development of Jiangbei New Area.
15
2017
/
06
Jiangsu Vcare and Yangzhou Princechem Acquired Boya Chemical Company
The signing ceremony of Jiangsu Vcare Pharmaceutical Technology Co., Ltd. and Yangzhou Princechem Co., Ltd. acquiring Boya Chemical (Nantong) Co., Ltd. was held in the conference room of Jiangsu Vcare recently. Boya Chemical (Nantong) Co., Ltd. is located in Yangkou Chemical Industrial Park, Rudong Coastal Economic Development Zone, Jiangsu Province. The company covers an area of 70 acres and is a Hong Kong-owned enterprise. The goal of this acquisition is to build Boya Chemical into a raw material drug manufacturer that meets the standards of China, the United States and the European Union. After renovation, Boya Chemical will be a chemical raw materials production base of Yatai Group and solve the bottleneck problem of Vcare's raw material drug R&D and production. It’s believed that the acquisition will make a significant contribution to Vcare’s production and sales of intermediates and APIs.
06
2017
/
06
Leaders of Management Committee of Rudong Coastal Economic Development Zone Visited Jiangsu Vcare
Leaders of management committee of Rudong coastal economic development zone visited Jiangsu Vcare on June 1st, 2017. The delegation was received by the vice chairman Jun Qu, general manager Yongqiang Liu, and vice general manager Yanchun Gong of Vcare. The delegation visited the Vcare's chemical research center and drug research center. Mr. Liu introduced R&D progress and advanced equipment to the guests. During the discussion, Mr. Liu introduced the overall development plan of Yatai Group's pharmaceutical industry, and Vcare's development history and the future plan. Mr. Liu also introduced the progress of innovative drug Vicagrel and a series of generic drugs in detail. The leaders of Rudong coastal economic development zone introduced the planning of their park, local investment, environmental protection policies and etc., and expressed their confidence in the research and development prospects of Vcare.